VHL Antibody

Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of VHL gene is the basis of familial inheritance of VHL syndrome. The protein is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein.

This VHL antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 181-210 amino acids from the C-terminal region of human VHL.

Store at 4˚ C for three months and -20˚ C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Olmos, G., Cell. Mol. Life Sci. 66 (13), 2167-2180 (2009) Hatzimichael, E., Clin Lymphoma Myeloma (3), 239-242 (2009) Luu, V.D., Clin. Cancer Res. 15 (10), 3297-3304 (2009)